Painamol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Painamol

What is Painamol? A Quick Overview

Property Description
Active ingredient Acetaminophen (Paracetamol)
Pharmacological class Analgesic and Antipyretic
Origin Synthetic Compound
Forms Tablet, Capsule, Liquid, Suppository, IV Solution
Common Use Relief of generalized pain and reduction of fever

Painamol is the proprietary designation for the common drug substance Acetaminophen, which is globally known as Paracetamol (INN). It is defined pharmacologically as a non-opioid analgesic and an antipyretic, placing it within the Para-aminophenol derivative class of medicines. Paracetamol is recognized as an essential medicine, underscoring its role as a fundamental, widely accessible option for symptom relief.


The Drug's Identity and Composition

Painamol is a synthetic organic compound typically manufactured and supplied as a single-ingredient product, featuring only Acetaminophen alongside necessary pharmaceutical excipients. This medicine is available in several high-level dosage forms, including the common tablet, capsule, and oral suspension for oral intake. It is also prepared as a suppository for rectal use and as a specialized intravenous solution for rapid administration in clinical settings. This diverse range of preparations allows the product to address different patient needs, ensuring flexibility in administration.


General Therapeutic Purpose

The overarching therapeutic purpose of Painamol is to effectively manage generalized pain and achieve the reduction of fever. The drug achieves these effects by acting mainly on the central nervous system to interfere with the production of key chemical messengers, called prostaglandins, that are involved in signaling pain and regulating the body's internal temperature. The antipyretic efficacy of Acetaminophen is clinically recognized as a standard of care for lowering a patient’s elevated body temperature.

Regulatory References

  1. Para-aminophenol derivative class of medicines
  2. prostaglandins

What side effects are possible with Painamol?

Possible side effects and safety information

The safety profile of Painamol (Acetaminophen/Paracetamol) is primarily documented in regulatory sources by classifications of adverse reactions across frequency and System-Organ Class (SOC). All statements below reflect official label information.

Official Adverse Reaction Scope

The most critical adverse reaction officially documented is severe hepatotoxicity, which is the potential for acute liver failure and death, overwhelmingly associated with exceeding the maximum recommended daily dose. This risk is heightened when the medication is taken concurrently with other acetaminophen-containing products.

Rare but serious consequences are also classified, including Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP). These very rare reactions are noted in regulatory documents as potentially occurring at first use or at any time during treatment. Severe systemic reactions like anaphylactic shock and angioedema are also documented as potential adverse effects with a Not Known frequency, meaning they cannot be estimated from available data.

Adverse effects are also categorized by the physiological systems involved, including Hepato-biliary Disorders, Skin and Subcutaneous Tissue Disorders, Immune System Disorders, and Blood and Lymphatic System Disorders (e.g., blood cell abnormalities like thrombocytopenia).

Population and Exposure Safety Constraints

The official label advises specific safety constraints. The medicine is contraindicated in cases of severe hepatic impairment or severe active liver disease. Caution is officially warranted in individuals with severe renal impairment and chronic alcohol users, where the hazard of liver toxicity is increased. Regulatory documents also note that prolonged, high-dose oral use may be associated with an increase in International Normalized Ratio (INR) in patients stabilized on certain anticoagulant medications.

Overdose and Emergency Response

Official Overdose Profile and Emergency Action

Overdose of Painamol (Acetaminophen/Paracetamol) is defined by official regulatory bodies as a time-critical medical emergency. The hepatic system is the primary system affected. The primary risk is severe liver damage leading to fulminant liver failure, which may necessitate liver transplantation or result in death.

Documented Manifestations and Risk

Initial symptoms may include nausea, vomiting, and abdominal pain. Crucially, regulatory documents state that severe manifestations, such as jaundice or confusion due to hepatic necrosis, are delayed, often appearing 24 to 48 hours post-ingestion. Patients may be asymptomatic during the initial hours, requiring a standardized, high-risk approach to management. Ingestion patterns officially noted include both single, large-quantity exposure and Repeated Supratherapeutic Ingestion (RSTI).

Urgent Help-Seeking and Treatment

Regulators mandate the immediate action to seek immediate medical attention or contact emergency services (e.g., Poison Help) for any suspected overdose. This must occur even if the individual reports feeling well, due to the delayed onset of life-threatening toxicity. An effective antidote, N-acetylcysteine (NAC), is documented in the prescribing information, but its use is time-critical for preventing permanent liver damage. Required procedures include continuous hospital monitoring and serial measurement of serum acetaminophen concentration and liver function tests.

Therapeutic Uses of Painamol

Painamol is used to provide symptomatic relief across two primary therapeutic domains: pain relief (analgesia) and fever management (antipyresis).


The medication is commonly used across conditions presenting with systemic or localized discomfort, helping to address symptoms related to physical discomfort. This includes common episodic manifestations such as tension headaches, muscle aches, joint pain, menstrual cramps, and discomfort following minor dental procedures. It is relevant in areas where short-term symptom management is appropriate for mild to moderate pain intensity. Painamol plays a role in managing elevated body temperature (fever) associated with acute episodes like the common cold or influenza, where it helps address symptom clusters that may become intense, including widespread body aches and general malaise.

“It provides a foundational layer of symptomatic support during episodes of heightened, yet temporary, distress.”

This support helps ease the overall symptom load and contributes to improved day-to-day comfort during symptomatic periods of illness. Painamol is relevant in scenarios where additional management of discomfort is required, such as post-immunization care.


Quick Fact: Use for Fever and Aches

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Painamol

The eligibility to use Painamol (Acetaminophen/Paracetamol) is defined by official regulatory documents, which stipulate who may use the medicine and under which conditions it is restricted or prohibited.

Absolute Contraindications

Painamol is contraindicated and must not be used by patients with a known hypersensitivity or allergy to Acetaminophen or any excipients in the formulation. Use is also strictly prohibited in patients with severe active liver disease or severe hepatic impairment.

Populations Requiring Conditional Use

Regulatory documents advise that the medicine be used with caution in several patient groups. This includes individuals with mild hepatic impairment, severe renal impairment (creatinine clearance leq 30 mL/min), or those with chronic conditions such as malnutrition or chronic excessive alcohol consumption.

Age and Physiological Status

Painamol is generally permitted for use across most age groups, from infants (two months and older) through adolescents and adults. For older adults, caution and potential maximum daily dose reduction are often advised if risk factors are present. Use is documented as compatible during both pregnancy and breastfeeding when clinically necessary.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Painamol (Acetaminophen/Paracetamol) is defined by documented alterations to its metabolic clearance, absorption kinetics, and pharmacodynamic effects on co-administered medicines.

Metabolic and Clearance Interactions

Substance/Category Official Interaction Description
Enzyme Inducers (e.g., Carbamazepine, Phenobarbital, Isoniazid, Rifampin) Co-administration is documented to increase the formation of the hepatotoxic metabolite, thereby increasing the risk of liver toxicity.
Chronic Heavy Alcohol Use Officially noted to significantly increase the risk of severe hepatotoxicity.
Probenecid Documented to inhibit the renal clearance of Painamol, resulting in increased plasma concentrations and higher exposure.
Zidovudine Co-administration may reduce the clearance of Zidovudine, potentially leading to increased exposure to the antiviral drug.

Pharmacodynamic and Absorption Interactions

Substance/Category Official Interaction Description
Oral Anticoagulants (e.g., Warfarin) Prolonged, daily co-administration may amplify the anticoagulant effect, increasing the risk of bleeding.
Cholestyramine Reduces the rate and extent of absorption; administration must be separated by at least one hour.
Metoclopramide and Domperidone Documented to increase the rate of absorption.

Population-Specific Notes

The risk of severe interaction leading to hepatotoxicity is officially documented as increased in populations with pre-existing hepatic impairment.

Mechanism of Action

The action of Painamol is fundamentally CNS-dominant, relying on synergistic mechanisms within the brain and spinal cord to modulate nociceptive signaling and thermoregulatory processes.

Modulating Central Prostaglandin Synthesis

This primary mechanism involves the peroxidase (POX) site of the COX enzyme in the central nervous system. By interfering with the enzyme's necessary redox cycle, the drug selectively limits the synthesis of Prostaglandin E2 ( PGE2). This molecular action directly affects the hypothalamus, resetting the body's thermoregulatory set-point, resulting in the initiation of heat-dissipating mechanisms.

Augmenting Endogenous Pain Control Systems

A key component of the resulting antinociceptive action involves the drug's metabolite, AM404. This metabolite modulates the body's natural anti-nociception systems by both activating the TRPV1 receptor and inhibiting the reuptake of anandamide, thereby enhancing signaling through the CB1 receptor. These actions increase the overall level of central antinociception and help attenuate the upward propagation of nociceptive signals in the spinal cord. This mechanism is functionally constrained by the local biochemical environment, exhibiting a preference for the low peroxide tone found in the CNS.

Dosage and Administration Information

How Painamol is Used: Official Administration Guidelines

Painamol (Acetaminophen/Paracetamol) administration is guided by protocols concerning route, dosage, and frequency, ensuring consistent application in clinical practice.

Administration Scope

Instruction Detail
Route of administration: Oral (tablet, liquid), Rectal (suppository), and Intravenous (IV) (infusion).
Dosing schedule (Adults ≥ 50 kg): Single doses are typically 650 mg or 1,000 mg. The maximum total daily dose across all administration routes must not exceed 4,000 mg in 24 hours.
Timing in relation to meals: Oral forms may be taken with or without food; administration without food may result in a faster onset of action.
Preparation requirements: The IV solution is administered solely as a 15-minute intravenous infusion; it is not for bolus injection. Liquid oral forms require the use of a provided dosing device for accurate volume measurement.

Frequency, Duration, and Population Adjustments

Administration is generally as-needed (PRN) for acute symptoms, requiring a minimum dosing interval of 4 hours between administrations. The total number of doses should not exceed four in a 24-hour period.

Painamol is indicated for short-term use for acute symptom management, and continuous use beyond 3 to 10 days is not recommended without further clinical evaluation. For patients with severe renal impairment (CrCl ≤ 30 mL/min), the labeled instructions warrant extended dosing intervals (e.g., 6 to 8 hours). Pediatric dosing is strictly determined based on body weight (mg/kg) to avoid exceeding lower maximum daily limits specific to age and weight.

Resulting Procedural Structure

The official protocol requires calculating the total daily dose from all administered forms to maintain the maximum limit, ensuring the minimum time interval is observed between doses, and adhering to specific administration constraints for the form used (e.g., IV infusion time, swallowing extended-release tablets whole).

Recent Clinical Evidence

This section provides a summary of the research evidence and clinical studies that have evaluated Painamol, using patient-friendly language that adheres to principles of neutrality and scientific transparency. It describes the scope of the research, the observations reported in studies, and areas where evidence remains limited or uncertain.

Evidence for Acute Pain Relief

Research on Painamol has primarily focused on research exploring outcomes related to physical discomfort that is episodic or temporary, mainly through short-term Randomized Controlled Trials (RCTs) and comprehensive reviews. These trials typically studied adults and adolescents with mild-to-moderate pain. The research has extensively monitored changes measured in the initial hours following a single dose, examining changes in pain intensity scores and the time until participants requested additional medication. While these findings describe patterns observed in the short-term, the follow-up durations were limited, and there is limited information for long-term outcomes regarding repeated self-administered use.

Evidence for Fever Management

Painamol was studied for outcomes related to systemic imbalance, specifically in studies observing elevated body temperature, known as antipyresis. This evidence is based on numerous controlled trials and systematic reviews across pediatric and adult populations. The research examined outcomes monitoring physiological strain, reporting measurements related to changes in elevated body temperature and the duration of the observed thermal patterns. However, data for certain groups remain insufficient, particularly for very young or low-birth-weight pediatric subgroups, and long-term effects are not fully established regarding the implications of antipyretic use in children over extended periods.

Research on Chronic Pain Conditions

Painamol was evaluated in conditions such as osteoarthritis and acute low back pain through intermediate-term RCTs. For people with osteoarthritis of the knee or hip, some studies reported small statistical changes in pain intensity measurements compared to placebo. However, these statistical changes appear to have low clinical relevance to patient-reported outcomes. For acute low back pain, systematic reviews of high-quality evidence indicate patterns suggesting research did not describe measured changes in pain intensity or disability. Follow-up durations were limited in these chronic pain trials, reinforcing that comparative evidence is lacking for many potential long-term scenarios.

Evidence in Special Populations and Uncertainty

Research has also explored Painamol in patient groups where evidence is often limited, including children, older adults, and certain pregnancy-related populations. The evidence quality varies across studies when moving beyond the common adult populations. For chronic conditions, the data show patterns related to modest statistical changes, but evidence is limited regarding whether these observations relate to perceived changes in daily functioning. The research provides context but not individual predictions, and the evidence highlights what is known — and what is still uncertain — regarding Painamol.

Key Studies & References

  1. The efficacy and safety of paracetamol for pain relief: an overview of systematic reviews
  2. Paracetamol (acetaminophen) - WHO Model List of Essential Medicines

Frequently Asked Questions (FAQ)

Common questions about Painamol (FAQ)

Q: What is the expected time for Painamol to start working?

Official regulatory documents and pharmacokinetic studies provide data on how quickly the medication is absorbed. The typical onset of action for an oral dose of Painamol is reported to be around 37 minutes in clinical studies. Specialized intravenous (IV) formulations, used in clinical settings, are reported to begin acting more rapidly.

Q: How long does the effect of one dose of Painamol last?

The duration of effect is related to the drug's half-life, which is the time it takes for the body to eliminate half of the medicine. The elimination half-life of Painamol (acetaminophen) is relatively short, typically falling between 1.9 and 2.5 hours. The short half-life is consistent with the official product information, which requires a minimum dosing interval of four hours between administrations.

Q: Is it possible for Painamol to cause drowsiness?

While drowsiness is not a common side effect of single-ingredient Painamol, official adverse event listings indicate that drowsiness or somnolence can be reported in rare instances. Because adverse effects like drowsiness may affect alertness, official warnings advise that individuals be aware of how the medicine affects them before engaging in activities that require full attention. This risk is generally higher when Painamol is part of a combination product containing a substance known to affect the central nervous system (CNS).

Q: Does Painamol interact with common supplements like Vitamin C or magnesium?

Regulatory sources generally focus on interactions with prescription drugs. However, some data suggest that high doses of Vitamin C (ascorbic acid) may increase the drug's levels in the body, which could potentially raise the risk of toxicity. In contrast, certain components of magnesium supplements, like citrate, may potentially decrease the rate of Painamol absorption. Any changes to or questions about supplement use should be discussed with a healthcare professional, as they are best positioned to assess individual needs.

Q: Is it normal to feel a mild headache after starting Painamol?

Although Painamol is primarily used to relieve headaches and pain, official post-marketing reports and clinical trial data sometimes list headache as a potential adverse event. Adverse effects are generally grouped by how frequently they are reported. Any persistent symptoms, including new or worsening headaches, are typically noted as a reason to seek medical review of the treatment plan.

Q: Does Painamol stay in your system for a long time?

Studies on the drug's pharmacokinetics show that Painamol has a short elimination half-life of approximately 2 to 2.5 hours. This means that the medicine is typically cleared from the system relatively quickly. The short half-life supports the requirement to maintain specific time intervals between doses.

Q: Can Painamol affect the results of lab tests?

Yes, official regulatory warnings indicate that the active ingredient in Painamol can interfere with certain clinical laboratory assays. Specifically, it is known to potentially cause false results with some measurement methods for blood glucose (sugar) and uric acid levels. Patients who have these tests performed are advised to inform the laboratory staff that they have recently taken Painamol.

Q: Can Painamol cause stomach upset or nausea?

Official product information, including summaries of adverse events, lists nausea and vomiting as potential gastrointestinal side effects. These effects are typically reported as uncommon or with a varying frequency across different formulations, such as the IV solution. If a person experiences persistent or severe gastrointestinal discomfort, the event should be reviewed by a healthcare professional.

Q: Is Painamol subject to any special legal controls or restrictions?

Single-ingredient Painamol (acetaminophen/paracetamol) is not classified as a controlled substance under most government regulations. However, it is essential to be aware that combination products containing Painamol combined with an opioid ingredient (such as codeine or hydrocodone) are classified and regulated as controlled substances.

Q: Why do some users report feeling 'restless' after taking Painamol?

Post-marketing data collected by regulatory agencies sometimes include reports of central nervous system effects such as restlessness or excitement. These are typically listed as uncommon or rare psychiatric or nervous system adverse effects. As with all medications, individual reactions can vary.

Q: Does Painamol interact with common psychiatric medications like SSRIs?

There is no major clinical interaction reported between Painamol and most Selective Serotonin Reuptake Inhibitors (SSRIs). However, official drug interaction data note that prolonged, daily use of Painamol can increase the risk of bleeding when taken with anticoagulants (blood thinners), and certain SSRIs also carry an elevated risk of bleeding. Because of the possible overlapping risk factors, healthcare professionals may need to monitor patients taking both Painamol and certain SSRIs.

Q: What is the evidence regarding Painamol's effectiveness for nerve pain?

Reviews of clinical evidence, often summarized by regulatory bodies, consistently note that the efficacy (effectiveness) of Painamol for treating specific types of neuropathic pain (nerve pain) is either limited or insufficient. Its primary role remains the relief of general aches, minor pain, and fever, rather than treating nerve pain.

Q: Are there any warnings about driving or operating machinery while taking Painamol?

Official warnings about driving are generally issued if the medication can cause side effects that affect a patient's alertness or coordination. Since Painamol can rarely cause effects like dizziness or drowsiness, warnings advise that individuals be aware of how the medicine affects them before driving or operating complex machinery.

Q: Can Painamol interact with caffeine or energy drinks?

Caffeine is frequently included as an active ingredient in combination Painamol products. Taking Painamol alongside high doses of caffeine from energy drinks or other sources may lead to side effects such as mathbfnervousness or mathbfirritability. Patients are advised to be mindful of their total caffeine intake from all sources while using this medication.

Q: Is Painamol safe for people with asthma?

According to official clinical guidelines, Painamol (acetaminophen) is often considered an appropriate alternative for patients who have mathbfaspirin-sensitive asthma. This is because it is typically less likely to trigger the asthma symptoms associated with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like aspirin or ibuprofen. Any use of Painamol by patients with asthma, or any pre-existing condition, typically requires review by a healthcare professional.

Q: Can Painamol cause dizziness or lightheadedness?

Official regulatory product information lists mathbfdizziness and mathbflightheadedness as possible adverse effects. The reported frequency of these effects can vary depending on the specific dosage form and the patient population. Because these effects may impair concentration, warnings advise that individuals be aware of how the medicine affects them before conducting tasks that require alertness.

Q: Does Painamol interfere with birth control pills?

Studies reviewed by regulatory bodies indicate that oral contraceptives (birth control pills) containing mathbfethinyl estradiol may potentially mathbfdecrease the effects of Painamol. However, at usual recommended therapeutic dosages, this interaction is generally not considered a clinically significant risk that requires routine dose adjustment or a change in contraception.

How should Painamol be stored and disposed of?

How to Store and Dispose of Painamol

The storage and disposal of Painamol (Paracetamol/Acetaminophen) must comply strictly with official regulatory requirements to ensure product stability and safety.


Storage Requirements

Requirement Official Condition
Temperature Store at controlled room temperature, not exceeding 30°C.
Protection Keep the product protected from light and moisture.
Container Store in the original container and keep it tightly closed.
Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Painamol must be disposed of in accordance with local regulations.

  • Regulatory agencies recommend utilizing authorized drug take-back programs or collection points.
  • Do not dispose of the medicine via wastewater or household drains.
  • Remove all personal information from labels before discarding the original packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Painamol found in:

A-Z Index: